Published in J Low Genit Tract Dis on July 01, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol (2011) 1.38
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol (2009) 1.31
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 1.22
Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis (2008) 1.20
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch (2011) 1.10
Clinical management of primary vulvar cancer. Eur J Cancer (2011) 1.10
Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res (2009) 1.10
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04
Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol (2011) 1.00
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer (2012) 0.98
Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol (2011) 0.97
Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer (2012) 0.93
Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol (2011) 0.92
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia (2002) 0.91
Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. Cancer (2006) 0.91
Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess (2010) 0.90
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. J Ovarian Res (2013) 0.89
Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer (2013) 0.89
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer (2010) 0.88
Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years. J Clin Virol (2009) 0.88
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases. Virchows Arch (2010) 0.87
Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP). Arch Gynecol Obstet (2012) 0.87
Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol (2012) 0.87
Morphologic characteristics of p16INK4a-positive cells in cervical cytology samples. Acta Cytol (2004) 0.85
Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients. BMC Cancer (2012) 0.84
Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer (2014) 0.84
Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT). J Ovarian Res (2013) 0.83
Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Hum Gene Ther (2003) 0.83
Risk factors for cervical human papillomavirus infection and high-grade intraepithelial lesion in women aged 20 to 31 years in Germany. Int J Gynecol Cancer (2013) 0.82
[Syphilis. Guideline of the German Sexually Transmitted Diseases Society fo diagnosis and therapy of syphilis]. J Dtsch Dermatol Ges (2006) 0.82
Squamous cell carcinoma arising from a localized vulval lesion of Hailey-Hailey disease after tacrolimus therapy. Am J Obstet Gynecol (2010) 0.81
Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer. Int J Gynecol Cancer (2011) 0.81
European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol (2013) 0.80
A patient-reported outcome measure to identify occurrence and distress of post-surgery symptoms of WOMen with vulvAr Neoplasia (WOMAN-PRO) - a cross sectional study. Gynecol Oncol (2013) 0.79
Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population. Int J Gynecol Cancer (2012) 0.79
Systemic treatment of vulvar cancer. Expert Rev Anticancer Ther (2015) 0.79
Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. Anticancer Res (2009) 0.78
Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer. Oncology (2013) 0.77
Characterization of squamous cell cancers of the vulvar anterior fourchette by human papillomavirus, p16INK4a, and p53. J Low Genit Tract Dis (2013) 0.77
Treatment of endometriosis with a VEGF-targeted conditionally replicative adenovirus. Fertil Steril (2009) 0.77
The superoxide anion is involved in the induction of long-term potentiation in the rat somatosensory cortex in vitro. Brain Res (2004) 0.76
Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri. Histopathology (2013) 0.76
Role of cyclin D1 amplification and expression in vulvar carcinomas. Hum Pathol (2012) 0.76
Platelet-activating factor contributes to the induction of long-term potentiation in the rat somatosensory cortex in vitro. Brain Res (2007) 0.76
Lymphadenectomy for pregnant women with stage I cervical cancer. Lancet (2012) 0.76
[HPV-associated anogenital neoplasia in HIV]. MMW Fortschr Med (2008) 0.75
Perceived Health-Related Quality of Life in Women With Vulvar Neoplasia: A Cross Sectional Study. Int J Gynecol Cancer (2016) 0.75
[Condylomata acuminata and other HPV associated disease pictures of the genitals, anus and urethra]. J Dtsch Dermatol Ges (2008) 0.75
[Activities of the Deutschen STD-Gesellschaft e.V. (Society for the Prevention of sexually transmitted diseases]]. Hautarzt (2009) 0.75
European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. Int J Gynecol Cancer (2017) 0.75
Incidence Patterns and Survival of Gynecological Sarcoma in Germany: Analysis of Population-Based Cancer Registry Data on 1066 Women. Int J Gynecol Cancer (2017) 0.75
Recurrent high-risk human papillomavirus-induced anogenital dysplasia in chronic idiopathic CD4+ T lymphocytopaenia. Acta Derm Venereol (2013) 0.75
Should Groin Recurrence Still Be Considered as a Palliative Situation in Vulvar Cancer Patients?: A Brief Report. Int J Gynecol Cancer (2016) 0.75
European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. Int J Gynecol Cancer (2017) 0.75
[A much promising trial with vaccine against HP viruses. Can a vaccination protect from cervix carcinoma?]. MMW Fortschr Med (2005) 0.75
Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment. Int J Gynecol Cancer (2015) 0.75
Adjuvant therapy in node-positive vulvar cancer. Expert Rev Anticancer Ther (2013) 0.75
Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Arch Gynecol Obstet (2008) 0.75